This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Arrowhead's Management Presents At 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript)

Unidentified Analyst

Is the platform is in the skincare I thought lot was in the skincare?

Christopher Anzalone

In the skincare, we do not have any candidates in skincare at this time.

Unidentified Analyst

First of all, it’s ingredients in the skincare all the time, right?

Christopher Anzalone

Probably not exactly we’re talking about here. I go into that platform in the next few slides that’s an interesting question now. Okay, now we are not just a platform company, we are also a product company we have a fairly robust for these (inaudible) company product pipeline, for peptide-drug conjugates our PDCs our first candidate or first PDC is called a dipeptide its against obesity. We have begun in Phase I study at MD Anderson Cancer Center about a month ago and so we are dosing patients as we speak. We also have a generic conjugate program in oncology that we are developing that’s still preclinical with in targeted RNAi, we have CALAA-01, which is an oncology, it’s a solid tumor, RNAi therapeutic, we’re finishing the Phase Ib in the next couple of weeks. Our next RNAi therapeutics is called ARC-520 that is again hepatitis B and we believe that we can file an IND in the second quarter of 2013. And we also have follow-on programs within our RNAi program, RNAi platforms probably the most advanced is against renal cell carcinoma.

Now I’ve got these two hepatitis in ARC-520 because read we think that those are potentially attractive to partners early. And the reason is because they’re both serving or addressing large underserved markets, we got very [contaminant] preclinical data in both we got unique amount of action in both, and we’ll talk about that in next several slides. And the trials are designed to provide early efficacy signals in both of those.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs